10-Q: Silexion Therapeutics Reports Q2 2026 Results, Faces Going Concern Doubt

Silexion Therapeutics Corp. filed its Q2 2026 Form 10-Q, detailing increased R&D expenses for its SIL204 trial, ongoing financing efforts, and substantial doubt regarding its ability to continue as a going concern.

Summary

• Silexion Therapeutics Corp. filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $6.3 million for the six months ended June 30, 2026, an increase from $4.2 million in the same period of 2025.
• Research and development expenses increased by 125% to $3.6 million for the six months ended June 30, 2026, primarily due to preparations for the Phase 2/3 clinical trial of SIL204.
• General and administrative expenses rose by 21.7% to $2.8 million for the same period, largely due to increased professional services costs.
• As of June 30, 2026, the company had $2.2 million in cash and cash equivalents and stated there is substantial doubt about its ability to continue as a going concern.
• The company is actively pursuing various financing activities, including at-the-market offerings and past public offerings, to fund its operations.
• A legal proceeding was initiated by Moringa Sponsor, L.P. disputing the conversion of a promissory note.
• The company received regulatory approvals in Israel and Germany to initiate its Phase 2/3 clinical trial for SIL204, with patient screening expected soon.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant operating losses, substantial doubt about the company's ability to continue as a going concern, and ongoing legal proceedings, despite progress in clinical trial preparations.

Positives

• Received formal regulatory approvals from the Israeli Ministry of Health and Germany's BfArM to initiate the Phase 2/3 clinical trial for SIL204.
• The Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer was initiated in July 2026.
• The company has actively engaged in multiple financing rounds, including public offerings and at-the-market sales, to secure capital.
• Successfully restored compliance with Nasdaq listing requirements after previous deficiencies.
• Increased authorized share capital to provide capacity for future equity issuances.
• Executed a 1-for-10 reverse share split to support share price and Nasdaq compliance.

Negatives

• Reported a net loss of $6.3 million for the six months ended June 30, 2026, and $3.6 million for the three months ended June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern, with current funds expected to last only several months.
• Operating expenses increased significantly, with R&D expenses up 125% and G&A expenses up 21.7% for the six-month period.
• The company has never generated revenue from product sales and may never be profitable.
• A legal claim has been filed by Moringa Sponsor, L.P. disputing the conversion of a promissory note and demanding repayment.
• The company's cash and cash equivalents were $2.2 million as of June 30, 2026, which is insufficient to meet anticipated cash requirements for the next 12 months.
• The company is heavily dependent on future financing, which may not be available on acceptable terms or at all.

Risks

• The Phase 2/3 clinical trials of SIL204 may not yield favorable results.
• The company has a limited operating history and has never generated revenue from product sales.
• Substantial additional funding is required, and there is no assurance it will be available on acceptable terms.
• The company may be unable to maintain compliance with Nasdaq Listing Rules, leading to delisting.
• The RNAi therapeutic approach for oncology is unproven and may never lead to marketable products.
• Reliance on third parties (CROs, manufacturers) whose performance is beyond the company's control.
• The ongoing legal proceeding initiated by Moringa Sponsor, L.P. could result in significant financial or operational impact.
• Geopolitical risks related to the company's operations in Israel and potential impact on financing activities.

Future Outlook

The company expects to continue incurring significant expenses and operating losses. Future expenses will depend on the advancement of clinical trials, regulatory applications, R&D activities, potential pipeline products, and hiring additional personnel. Substantial additional funding is required to finance operations, expand the business, and maintain Nasdaq compliance.

Management Comments

• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued.
• We expect to continue to incur significant expenses and operating losses for the foreseeable future.
• We will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which would likely cause dilution to our shareholders.
• We believe that the conversions were carried out in strict compliance with the substantive and procedural requirements of the note, and refute all arguments made by the Moringa Sponsor to the contrary.
• We believe our current cash and cash equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash requirements for the next 12 months from the filing date of this quarterly report, but rather through the fourth quarter of 2026 under our current business plan.

Industry Context

StockSavvy.ai notes that Silexion Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on RNAi therapies for KRAS-driven cancers. The company's reliance on frequent financing rounds and its ongoing struggle with Nasdaq listing compliance are common challenges for development-stage biotechs. The initiation of its Phase 2/3 trial for SIL204 is a critical step, but the significant operating losses and going concern issues highlight the inherent risks in this industry.

Comparison to Industry Standards

• Many clinical-stage biotechnology companies, like Silexion, experience significant operating losses and rely heavily on external financing to fund R&D and clinical trials.
• The need for substantial capital raises is standard in the industry, often leading to shareholder dilution, a common concern for investors in this sector.
• Maintaining Nasdaq listing standards, particularly minimum bid price and shareholders' equity, is a frequent challenge for smaller biotech firms, often requiring reverse stock splits or equity financings.
• The development timeline for novel therapeutics, such as Silexion's SIL204, is lengthy and expensive, with high failure rates, which is a benchmark risk across the industry.

Corporate Governance

Legal Proceedings

• Moringa Sponsor, L.P. filed a claim on June 22, 2026, disputing the conversion of a portion of the Related Party Promissory Note into ordinary shares and demanding full repayment plus damages. The company believes the claim is baseless and intends to defend itself vigorously, considering a counterclaim.

Related Party Transactions

• The company has an outstanding Related Party Promissory Note with Moringa Sponsor, L.P. with a principal amount of $0.2 million as of the filing date.
• During the six months ended June 30, 2026, $0.6 million of the Related Party Promissory Note was converted into 153,320 ordinary shares.
• Research and development expenses included $176 thousand from a related party for the six months ended June 30, 2026.
• General and administrative expenses included $282 thousand from a related party for the six months ended June 30, 2026.

Stakeholder Impact

• Shareholders may experience significant dilution due to ongoing and future equity financings.
• The company's ability to continue as a going concern poses a risk to all stakeholders, potentially leading to a loss of investment.
• The legal dispute with Moringa Sponsor, L.P. could impact the company's financial stability and management's focus.
• Employees may face uncertainty regarding job security due to the going concern issues and the need for potential restructuring or further financing.

Next Steps

• Initiate patient screening for the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.
• Continue to monitor developments related to geopolitical conflicts and assess potential impacts.
• Continue to pursue financing alternatives to fund future operations and research and development activities.
• Defend vigorously against the legal claim filed by Moringa Sponsor, L.P.
• Seek marketing approvals for SIL204 in various territories.
• Apply for Orphan Drug Designation in both the U.S. and EU for SIL204.

Key Dates

Recommendation

The company is in a high-risk, high-reward phase with its lead drug candidate in clinical trials. While progress has been made in trial initiation and financing efforts, the significant operating losses, substantial doubt about going concern, and ongoing legal proceedings present considerable risks. The potential for a breakthrough with SIL204 is offset by these severe financial and legal challenges, making a 'hold' recommendation appropriate for investors with a high-risk tolerance, while new investment should be approached with extreme caution.

Keywords

biotechnology, RNAi therapeutics, KRAS-driven cancers, pancreatic cancer, SIL204, clinical trials, biotech financing, Nasdaq compliance